{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T07:09:18Z","timestamp":1777792158540,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurocrit Care"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Factor Xa inhibitors are widely used anticoagulants but are associated with a known risk of bleeding complications. In 2018, andexanet alfa was approved as an antidote for the reversal of apixaban and rivaroxaban, demonstrating high efficacy in controlling intracranial hemorrhage. However, data on its use prior to neurosurgical procedures remain limited. Here, we present our experience with andexanet alfa in patients undergoing emergency cranial neurosurgical procedures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Here, we present a case series based on a retrospective analysis conducted over a four-year period, identifying patients who underwent cranial neurosurgical procedures while on factor Xa inhibitors and treated with andexanet alfa at two tertiary academic neurosurgical centers in Germany. We reviewed demographic, clinical, and medical data, including age, sex, diagnosis, neurological status, laboratory results, surgical protocols, and imaging studies. The primary end points were (1) the efficacy of andexanet alfa in preventing secondary bleeding during or after surgery (hemostatic efficacy) and (2) its safety concerning ischemic events. Hemostatic efficacy was assessed via postoperative computed tomography scans performed six hours after surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 29 patients (14\u00a0female, 15\u00a0male) underwent 34 neurosurgical procedures (18 burr-hole craniostomies [BHs] and 16 craniotomies [CRAs]). The patients\u2019 ages ranged from 55 to 94\u00a0years (mean 74.82\u2009\u00b1\u200910.65). The median Glasgow Coma Scale score was 7 at admission. In total, postoperative computed tomography scans revealed no or only minor hematoma in 94% of patients (BH in 94% vs. CRA in 94%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.99). Ischemic events occurred in 9 patients, including 8 cases of cerebral ischemia and one case of mesenteric ischemia (BH: 28%; CRA: 31%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.99). No cases of deep vein thrombosis or pulmonary embolism were recorded. The use of additional hemostatic agents was associated with the occurrence of ischemic events (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04, 95% confidence interval 1.11\u2013122.77, odds ratio 11.7). Overall, in-hospital mortality was 28% in total.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings suggest that andexanet alfa is highly effective in preventing secondary bleeding during neurosurgery in patients on factor Xa inhibitors. However, the risk for ischemic events must be carefully considered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12028-025-02393-z","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T23:52:49Z","timestamp":1763682769000},"page":"568-577","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Andexanet Alfa in Emergency Cranial Neurosurgical Procedures: A Bicentric Analysis of Efficacy and Safety"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7976-7113","authenticated-orcid":false,"given":"Harold F.","family":"Hounchonou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolin","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Jelinek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Wild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manolis","family":"Polemikos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Abu-Fares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Negwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shadi","family":"Al-Afif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim K.","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"issue":"7","key":"2393_CR1","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/j.jtha.2023.04.021","volume":"21","author":"JC Fredenburgh","year":"2023","unstructured":"Fredenburgh JC, Weitz JI. News at XI: moving beyond factor Xa inhibitors. J Thromb Haemost. 2023;21(7):1692\u2013702.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2393_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrcardio.2017.223","volume":"15","author":"JH Levy","year":"2018","unstructured":"Levy JH, Douketis J, Weitz JI. Reversal agents for non-vitamin K antagonist oral anticoagulants. Nat Rev Cardiol. 2018;15(5):273\u201381.","journal-title":"Nat Rev Cardiol"},{"issue":"9921","key":"2393_CR3","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955\u201362.","journal-title":"Lancet"},{"key":"2393_CR4","doi-asserted-by":"crossref","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391","DOI":"10.1056\/NEJMoa1009638"},{"issue":"11","key":"2393_CR5","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392.","journal-title":"N Engl J Med"},{"issue":"10","key":"2393_CR6","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s40265-018-0940-4","volume":"78","author":"YA Heo","year":"2018","unstructured":"Heo YA. Andexanet alfa: first global approval. Drugs. 2018;78(10):1049\u201355.","journal-title":"Drugs"},{"issue":"25","key":"2393_CR7","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","volume":"373","author":"DM Siegal","year":"2015","unstructured":"Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373(25):2413\u201324.","journal-title":"N Engl J Med"},{"issue":"13","key":"2393_CR8","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","volume":"147","author":"TJ Milling Jr","year":"2023","unstructured":"Milling TJ Jr, Middeldorp S, Xu L, Koch B, Demchuk A, Eikelboom JW, et al. Final study report of andexanet alfa for major bleeding with factor Xa inhibitors. Circulation. 2023;147(13):1026\u201338.","journal-title":"Circulation"},{"key":"2393_CR9","unstructured":"Connolly SJ, Sharma M, Cohen AT, Demchuk AM, Czlonkowska A, Lindgren AG, et al; 2024 ANNEXA-I Investigators. Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage. N Engl J Med. 390(19):1745\u201355."},{"issue":"6","key":"2393_CR10","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1161\/STROKEAHA.111.640284","volume":"43","author":"BA Gregson","year":"2012","unstructured":"Gregson BA, Broderick JP, Auer LM, Batjer H, Chen X-C, Juvela S, et al. Individual patient data subgroup meta-analysis of surgery for spontaneous supratentorial intracerebral hemorrhage. Stroke. 2012;43(6):1496\u2013504.","journal-title":"Stroke"},{"issue":"10","key":"2393_CR11","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/phar.2727","volume":"42","author":"PG Bradshaw","year":"2022","unstructured":"Bradshaw PG, Keegan SP, Droege ME, Dykes NJH, Ernst NE, Foertsch MD, et al. Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures. Pharmacotherapy. 2022;42(10):780\u201391.","journal-title":"Pharmacotherapy"},{"key":"2393_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2023.107621","volume":"226","author":"AA Ammar","year":"2023","unstructured":"Ammar AA, Elsamadicy AA, Ammar MA, Reeves BC, Koo AB, Falcone GJ, et al. Emergent external ventricular drain placement in patients with factor Xa inhibitor-associated intracerebral hemorrhage after reversal with andexanet alfa. Clin Neurol Neurosurg. 2023;226:107621.","journal-title":"Clin Neurol Neurosurg"},{"key":"2393_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2020.106070","volume":"195","author":"A Giovino","year":"2020","unstructured":"Giovino A, Shomo E, Busey KV, Case D, Brockhurst A, Concha M. An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage. Clin Neurol Neurosurg. 2020;195:106070.","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"2393_CR14","doi-asserted-by":"publisher","first-page":"E21","DOI":"10.1002\/ajh.25326","volume":"94","author":"SE Culbreth","year":"2019","unstructured":"Culbreth SE, Rimsans J, Sylvester K, Pallin DJ, Connors JM. Andexanet alfa-the first 150 days. Am J Hematol. 2019;94(1):E21\u20134.","journal-title":"Am J Hematol"},{"issue":"7","key":"2393_CR15","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1161\/STROKEAHA.117.017866","volume":"48","author":"JP Broderick","year":"2017","unstructured":"Broderick JP, Adeoye O, Elm J. Evolution of the modified Rankin scale and its use in future stroke trials. Stroke. 2017;48(7):2007\u201312.","journal-title":"Stroke"},{"key":"2393_CR16","doi-asserted-by":"crossref","unstructured":"Kan P, Fiorella D, Dabus G, Samaniego EA, Lanzino G, Siddiqui AH, et al; ARISE I Academic Industry Roundtable. ARISE I consensus statement on the management of chronic subdural hematoma. Stroke. 2024;55(5):1438\u201348.","DOI":"10.1161\/STROKEAHA.123.044129"},{"issue":"4","key":"2393_CR17","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.ajem.2019.12.008","volume":"38","author":"CS Brown","year":"2020","unstructured":"Brown CS, Scott RA, Sridharan M, Rabinstein AA. Real-world utilization of andexanet alfa. Am J Emerg Med. 2020;38(4):810\u20134.","journal-title":"Am J Emerg Med"},{"issue":"1","key":"2393_CR18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11239-021-02495-3","volume":"53","author":"ML Vestal","year":"2022","unstructured":"Vestal ML, Hodulik K, Mando-Vandrick J, James ML, Ortel TL, Fuller M, et al. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage. J Thromb Thrombolysis. 2022;53(1):167\u201375.","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"2393_CR19","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/MBC.0000000000001279","volume":"35","author":"VM Irizarry-Gatell","year":"2024","unstructured":"Irizarry-Gatell VM, Bacchus MW, De Leo EK, Zhang Y, Lagasse CA, Khanna AY, et al. The use of andexanet alfa vs. 4-factor prothrombin complex concentrates in the setting of life-threatening intracranial hemorrhage. Blood Coagul Fibrinolysis. 2024;35(3):94\u2013100.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"2393_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s11239-022-02715-4","volume":"55","author":"C Troyer","year":"2023","unstructured":"Troyer C, Nguyen W, Xie A, Wimer D. Retrospective review of andexanet alfa versus 4- factor prothrombin complex concentrate for reversal of DOAC-associated intracranial hemorrhage. J Thromb Thrombolysis. 2023;55(1):149\u201355.","journal-title":"J Thromb Thrombolysis"},{"key":"2393_CR21","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s12028-024-02130-y","volume":"42","author":"K Sarhan","year":"2024","unstructured":"Sarhan K, Mohamed RG, Elmahdi RR, Mohsen Y, Elsayed A, Zayed DM, et al. Efficacy and safety of andexanet alfa versus four factor prothrombin complex concentrate for emergent reversal of factor Xa inhibitor associated intracranial hemorrhage: a systematic review and meta-analysis. Neurocrit Care. 2024;42:701\u201314.","journal-title":"Neurocrit Care"},{"issue":"4","key":"2393_CR22","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s11239-018-1645-y","volume":"45","author":"S Piran","year":"2018","unstructured":"Piran S, Gabriel C, Schulman S. Prothrombin complex concentrate for reversal of direct factor Xa inhibitors prior to emergency surgery or invasive procedure: a retrospective study. J Thromb Thrombolysis. 2018;45(4):486\u201395.","journal-title":"J Thromb Thrombolysis"},{"issue":"1","key":"2393_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40560-018-0303-y","volume":"6","author":"J Tao","year":"2018","unstructured":"Tao J, Bukanova EN, Akhtar S. Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors. J Intensive Care. 2018;6(1):34.","journal-title":"J Intensive Care"},{"issue":"3","key":"2393_CR24","first-page":"201","volume":"71","author":"CV Gianserra","year":"2011","unstructured":"Gianserra CV, Ag\u00fcero AP, Chapelet AG, Paradiso B, Spanevello VA, Del Pino MA. Hospital-acquired anemia and decrease of hemoglobin levels in hospitalized patients. Medicina (B Aires). 2011;71(3):201\u20136.","journal-title":"Medicina (B Aires)"},{"issue":"11","key":"2393_CR25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.40145","volume":"5","author":"R Chaudhary","year":"2022","unstructured":"Chaudhary R, Singh A, Chaudhary R, Bashline M, Houghton DE, Rabinstein A, et al. Evaluation of direct oral anticoagulant reversal agents in intracranial hemorrhage: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(11):e2240145.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2393_CR26","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.bpa.2009.09.012","volume":"24","author":"VG Nielsen","year":"2010","unstructured":"Nielsen VG, Asmis LM. Hypercoagulability in the perioperative period. Best Pract Res Clin Anaesthesiol. 2010;24(1):133\u201344.","journal-title":"Best Pract Res Clin Anaesthesiol"},{"issue":"1","key":"2393_CR27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12893-016-0128-3","volume":"16","author":"J Ulrych","year":"2016","unstructured":"Ulrych J, Kvasnicka T, Fryba V, et al. 28 day post-operative persisted hypercoagulability after surgery for benign diseases: a prospective cohort study. BMC Surg. 2016;16(1):16.","journal-title":"BMC Surg"},{"issue":"2","key":"2393_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s11239-022-02658-w","volume":"54","author":"PG Bradshaw","year":"2022","unstructured":"Bradshaw PG, Keegan S, Foertsch M, Yang GL, Ngwenya LB, Srinivasan V. Andexanet alfa after 4-factor PCC administration for intracranial hemorrhage: a case series. J Thromb Thrombolysis. 2022;54(2):295\u2013300.","journal-title":"J Thromb Thrombolysis"},{"issue":"15","key":"2393_CR29","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.021845","volume":"10","author":"WS Dodd","year":"2021","unstructured":"Dodd WS, Laurent D, Dumont AS, Hasan DM, Jabbour PM, Starke RM, et al. Pathophysiology of delayed cerebral ischemia after subarachnoid hemorrhage: a review. J Am Heart Assoc. 2021;10(15):e021845.","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"2393_CR30","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1007\/s00134-021-06548-2","volume":"47","author":"C Sandroni","year":"2021","unstructured":"Sandroni C, Cronberg T, Sekhon M. Brain injury after cardiac arrest: pathophysiology, treatment, and prognosis. Intensive Care Med. 2021;47(12):1393\u2013414.","journal-title":"Intensive Care Med"},{"issue":"Suppl 1","key":"2393_CR31","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1007\/s10072-004-0207-6","volume":"25","author":"M Collice","year":"2004","unstructured":"Collice M, D\u2019Aliberti G, Talamonti G, Bacigaluppi S. Surgery for intracerebral hemorrhage. Neurol Sci. 2004;25(Suppl 1):S10\u20131.","journal-title":"Neurol Sci"}],"container-title":["Neurocritical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-025-02393-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12028-025-02393-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12028-025-02393-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:57:50Z","timestamp":1775491070000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12028-025-02393-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2393"],"URL":"https:\/\/doi.org\/10.1007\/s12028-025-02393-z","relation":{},"ISSN":["1541-6933","1556-0961"],"issn-type":[{"value":"1541-6933","type":"print"},{"value":"1556-0961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"15 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest to declare.\n                      Ethical Approval\/Informed Consent\n                      This study was conducted in accordance with the Declaration of Helsinki. For this type of study, formal approval of the institutional ethics committee of the Medical School Hannover is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}